Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9544920 | 0.98 | TDP1 (0.45) | TDP1CYP3A4ALDH1A1MAPK1TP53 | |
| SCHEMBL18562081 | 0.89 | BRAF (0.41) | ALDH1A1ALOX15TSHRBRAFDGAT1 | |
| SCHEMBL31123215 | 0.89 | TDP1 (0.41) | TDP1CYP3A4ALDH1A1MAPK1TP53 | |
| SCHEMBL29659336 | 0.89 | CYP3A4 (0.43) | TDP1CYP3A4ALDH1A1MAPK1TP53 | |
| SCHEMBL6387899 | 0.83 | ALDH1A1 (0.38) | TDP1CYP3A4ALDH1A1MAPK1TP53 | |
| SCHEMBL16914897 | 0.83 | ALDH1A1 (0.59) | TDP1CYP3A4ALDH1A1MAPK1TP53 | |
| SCHEMBL23928152 | 0.82 | TAAR1 (0.47) | TDP1ALDH1A1MAPK1TSHRL3MBTL1 | |
| SCHEMBL994614 | 0.82 | TDP1 (0.54) | TDP1CYP3A4ALDH1A1MAPK1TP53 | |
| SCHEMBL10216056 | 0.82 | ALDH1A1 (0.44) | ALDH1A1TSHRBRAFDGAT1MAPT | |
| SCHEMBL5691620 | 0.80 | CTH (0.43) | TDP1CYP3A4ALDH1A1MAPK1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250221998-A1 | DISCOVERY OF COVALENT EGFR INHIBITOR THROUGH CYSTEINE 775 | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2025-07-10 | — | — | US | disclosed |
| EP-4504730-A1 | DISCOVERY OF COVALENT EGFR INHIBITOR THROUGH CYSTEINE 775 | Dana-Farber Cancer Institute, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| CN-119365454-A | Discovery of covalent EGFR inhibitors through cysteine 775 | 丹娜-法伯癌症研究院 | 2025-01-24 | — | — | CN | disclosed |
| WO-2023196409-A1 | DISCOVERY OF COVALENT EGFR INHIBITOR THROUGH CYSTEINE 775 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023196409-A1 | DISCOVERY OF COVALENT EGFR INHIBITOR THROUGH CYSTEINE 775 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-10562918-B2 | Heterocyclic compounds and uses thereof | ACEA Therapeutics, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
| EP-3019496-B1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | ACEA THERAPEUTICS INC (US) | 2019-09-11 | — | — | EP | disclosed |
| EP-3484887-A1 | WEE-1 INHIBITING PYRAZOLOPYRIMIDINONE COMPOUNDS | Almac Discovery Limited (GB) | 2019-05-22 | — | — | EP | disclosed |
| US-10000482-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| WO-2013171281-A1 | HYDANTOIN AND THIOHYDANTOIN DERIVATIVES AS ANTIVIRAL DRUGS | VIVALIS (FR) | 2013-11-21 | — | — | WO | disclosed |
| EP-2664616-A1 | Hydantoin and thiohydantoin derivatives as antiviral drugs | Vivalis (FR) | 2013-11-20 | — | — | EP | disclosed |
| US-20120329785-A1 | Novel kinase inhibitors | ORIGENIS GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| US-20120329780-A1 | Novel kinase inhibitors | ORIGENIS GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| US-20100216791-A1 | PYRIDINYLQUINAZOLINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | ASTRAZENECA (SE) | 2010-08-26 | — | — | US | disclosed |
| EP-2038253-A1 | BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C | Arrow Therapeutics Limited (GB) | 2009-03-25 | — | — | EP | disclosed |
| WO-2007138242-A1 | BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C | ARROW THERAPEUTICS LIMITED (GB) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007138242-A1 | BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C | ARROW THERAPEUTICS LIMITED (GB) | 2007-12-06 | — | — | WO | disclosed |
| EP-0384487-A2 | Silver halide color photographic material | Fuji Photo Film Co., Ltd. (JP) | 1990-08-29 | — | — | EP | disclosed |
| US-4113490-A | DEVELOPMENT, AMPLIFYING BATH CONTAINING HYDROGEN PEROXIDE | KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) | 1978-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562918-B2 | Heterocyclic compounds and uses thereof | BMX, BLK, BTK | TDP1 1300/4885CYP3A4 2847/4885ALDH1A1 4165/4885 |
| US-20100216791-A1 | PYRIDINYLQUINAZOLINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | BRAF, RAF1, ARAF | TDP1 1814/4885CYP3A4 1522/4885ALDH1A1 948/4885 |
| US-20120329780-A1 | Novel kinase inhibitors | LRRK2, MYLK2, MYLK | TDP1 1953/4885CYP3A4 4198/4885ALDH1A1 4333/4885 |
| US-20120329785-A1 | Novel kinase inhibitors | LRRK2, MYLK2, MYLK3 | TDP1 725/4885CYP3A4 4807/4885ALDH1A1 4394/4885 |
| US-10000482-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | TDP1 1914/4885CYP3A4 4148/4885ALDH1A1 4184/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | TDP1 1914/4885CYP3A4 4148/4885ALDH1A1 4184/4885 |
| US-20250221998-A1 | DISCOVERY OF COVALENT EGFR INHIBITOR THROUGH CYSTEINE 775 | EGFR, ERBB2, ERBB3 | TDP1 3122/4885CYP3A4 4714/4885ALDH1A1 2954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.